The antibody-mediated targeting of TLT-1 reduced tumor growth and enhanced the tumor infiltration of CD8 T cells in mice, while blocking platelet TLT-1 in NSCLC patient samples ex vivo could rescue the CD8 T cells. The gene discussed is CD8A; the disease is neoplasm.